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Introduction
Caspofungin is an echinocandin antifungal agent licensed as a first-line therapy for invasive candidiasis in patients with moderate to severe illness or recent exposure to azoles [1] . The recommended dosage regimen of caspofungin is a loading dose of 70 mg followed by 50 mg daily (70/50 mg), administered intravenously over 1 h. Caspofungin is highly protein bound (96%) and metabolizes slowly in the liver [2] [3] [4] . Its liver uptake is a biphasic process and its binding to the surface of hepatocytes is fast and reversible. Studies demonstrated that the uptake of caspofungin by liver is related to the active organic anion transporting polypeptide 1B1 (OATP1B1) [5] . The plasma clearance (CL) of caspofungin is 10 to 12 mL/min [2] . It is eliminated mainly by hepatic, for only one to two percent of the antifungal agent is through renal clearance [6] . The elimination of caspofungin from plasma is slow and the half-life of caspofungin is 9-11 h [2] . Clinically, pharmacokinetics (PK) parameters in intensive care unit (ICU) patients are often different from those in healthy subjects [7] . Factors associated with alterations in PK include changes in organ function, use of extracorporeal clearance techniques and drug interactions [8, 9] . It was also reported that caspofungin plasma concentrations were influenced by hypoalbuminaemia and hepatic impairment (HI) [7] . One study demonstrated that caspofungin trough plasma concentrations (C min ) ranges were relatively wide in surgical ICU patients and [7] . Another study showed that caspofungin area under the curve (AUC) was increased by 55% and 76% in patients with mild and moderate HI, respectively [4, 10] . But at present, data are very limited and absent on these special patients, an increase in knowledge on these patients should be considered. Clinically, patients weighing >80 kg are advised to receive a dosage regimen of 70/70 mg [11] . But studies of general ICU population and hematopoietic stem cell transplantation patients found that body weight (BW) (range 50-99 kg) had no effect on caspofungin PK [9, 12] .
not clear. On the other hand, one study demonstrated that the vast majority of fungal infections are caused by Candida spp [9] . In the critically ill, the infections of invasive Candida spp. are associated with high crude and attributable mortalities as high as 60% and 40%, respectively [13] . One multicentre observational study in Spain had carried out that mortality was associated with age, Candida spp., different from C. parapsilosis and inadequate treatment [14] . All of these ask for a model which could predict the PK of caspofungin in different populations (general patients, ICU patients and HI patients) with different physical conditions, BW, age, race, Candida spp. And based on the PK parameters, a Monte Carlo simulation (MCS) could be used to optimize the clinical dosage regimens of caspofungin in different patient populations.
Whole-body physiology-based PK (WB-PBPK) modellings consider the physical and chemical characteristics of a drug and it also give thorough consideration of physiological processes of drug absorption, distribution, metabolism and elimination accurately [15] . Based on a series of parameters, such as physiological and physicochemical properties, CL, distribution into tissues and metabolism or active transport, WB-PBPK could predicts PK of a drug [15] . Then based on a series of equations, we can develop a WB-PBPK model which could be applied to forecast disease dependencies [7, 9] , BW, age, and race can also be used to investigate the variability expected in different patient populations [6, 12] . The aim of the present study was to build and verify a WB-PBPK model which could predict the PK of caspofungin in general patients, ICU patients with Child-Pugh B, ICU patients on continuous renal replacement therapy (CRRT) and HI patients, then to evaluate the impact on the PK of caspofungin between different individuals through stochastic simulations of different body weight, age and race using the validated WB-PBPK model. Finally, combined with MCS technique to help in the selection of a safe and effective administration scheme after simulation of the potential exposure and disposition in different patient populations.
Materials and methods

PK data
Clinical PK data for intravenous administration of caspofungin in healthy adults and all patients were obtained from the literature [4, 9, 10, 16, 17] . Raw data of 20 healthy subjects, receiving single intravenous doses of 20 mg, 40 mg, 70 mg, 100 mg, respectively, were used for model development. The mean age was 29 years (range, 21-39 years) and the mean weight was 75 kg (range, 60-88 kg). The observed mean concentrations of caspofungin over time were from the literature [4] . Mean concentrations of caspofungin over time from a doubleblind, placebo-controlled, serial-panel study of 24 healthy male subjects to investigate the pharmacokinetics of caspofungin following daily doses of 15, 35, or 70 mg were used to validate the model [4] . Another trial of caspofungin in healthy subjects studied the standard dosage regimen of 70/50 mg [10] . Plasma drug profiles defined by concentrations at 0 h (predose) and at 0. 5, 0.75, 1, 1.25, 1.5, 2, 4, 8, 12 , and 24 h postdose were obtained on days 1 and 14. Intervening trough (24-h postdose) concentrations (C min ) were obtained prior to dosing on d 3, 4, 7, and 10 [4] . The relevant data are shown in Table 1 . To develop and qualify the WB-PBPK model in general patients [16] , ICU patients with Child-Pugh B [9] and ICU patients on CRRT [17] , HI patients [10] , raw data from 4 clinical trials were used. The study description, population included, treatment schedule, doses and sampling scheme are shown in Table  1 . The study of general patients was a formal phase II dose escalation trial in patients with invasive aspergillosis. Caspofungin was administered once daily as an iv infusion over 120 min at 70 mg (9 patients), 100 mg (8 patients), 150 mg (9 patients) and 200 mg (20 patients). Pharmacokinetic sampling was performed serially on d 1 (2, 3, 5-7 and 24 h after the infusion started) and peak (at the end of infusion) and trough levels (immediately before the next infusion started) were collected on d 4, 7, 14 and 28. All observed data from pharmacokinetic sampling were pooled as mean±standard deviation [16] . Depending on the WB-PBPK model, we studied the recommended dosage regimens (70/50 mg in ICU patients, mild HI; 70/35 mg in moderate HI patients) of caspofungin [9, 10, 17] . To evaluate the model, we collected 508 trough concentrations from 161 patients (39 ICU patients with Child-Pugh B, 16 ICU patients on CRRT, 47 moderate HI patients and 68 mild HI -versity. The pharmacokinetic sampling were pooled as mean± standard deviation in ICU patients and HI patients. The study informed consent before any screening item being performed.
Model development
The WB-PBPK model of caspofungin, which was built by GastroPlus version 9.0 (Simulations Plus, USA), was used for all of the simulations in healthy subjects. The WB-PBPK (disposition) model was composed of a number of tissue compartments which were linked together by venous and arterial blood circulation. These compartments include the heart, lung, brain, adipose, muscle, skin, liver, kidney, and so on. The drug distribution into different compartments was driven by perfusion-limited kinetics for all of the tissues were considered to be well-stirred compartments. Each compartment was defined by an associated tissue blood flow rate, volume and mass balance differential equations to develop the model [18] . Vital physicochemical parameters and the key vitro data for caspofungin are depicted in Table 2 . The pK a , Rbp, solubilitypH, effective permeability and particle size were obtained using the ADMET Predictor TM module of GastroPlus. Human logP, fup (plasma unbound drug) was obtained from the related literature [19, 20] . The tissue-to-plasma partition coefficients of caspofungin were calculated using established tissuecomposition based models. Total plasma CL of caspofungin was calculated by the PKplus model of the GastroPlus version 9.0 (Table 3) . The results of non-compartment model will be used to develop the WB-PBPK model. The main elimination route of caspofungin is hepatic (98%) and only two percent of caspofungin is through renal clearance. So the CL data of liver and renal used in the model will based on this. The simulation time was 144 h and the volume of dosage administration was 250 mL.
PK simulations
Based on the raw data from 4 clinical trials, we developed and qualified the WB-PBPK model in general patients, ICU patients with Child-Pugh B and ICU patients on CRRT and HI patients. The study description, population included, treatment schedule, doses and sampling scheme were recorded models. Total plasma CL from different populations were calculated by the PKplus model of the GastroPlus version 9.0 (Table 3) . The results of non-compartment model were used to develop the WB-PBPK model. The simulation time were 14 d and the volume of dosage administration were 250 mL.
Model evaluation
To evaluate the WB-PBPK models, a visual comparison between the predicted data of GastroPlus version 9.0 and the observed data (literature resources and our research data) of the different trials from different populations was carried out. Goodness of fit (GOF) plots were performed to analyze the accuracy between simulated and observed data. The prediction error (PE) was estimated according to Eq. 1 [19] .
PE=(simulated-observed)/observed×100 (Eq.1) The fold-error, which represents the difference between observed and predicted in vivo values, was used to assess the accuracy of the predicted PK parameters, and if the fold-error was less than two, the prediction was considered successful [21, 22] .
Fold-error=observed/predicted (observed value > predicted value) (Eq.2) Fold-error=predicted/observed (observed value < predicted value) (Eq.3)
Model application Virtual trial simulations
For general and ICU patients, we simulated the recommended dosage regimens (70/50 mg) of caspofungin. On the other hand, other two multiple dosage regimens (70/35 mg, 70/70 mg, 100/100 mg) of caspofungin were simulated to investigate the effects of different dosage regimens of caspofungin in these patients. For HI patients, except the recommended dosage regimens (70/35 mg for moderate HI patients, 70/50 mg for mild HI patients), dose reduction of 50/25 mg and dose escalating of 70/70 mg, 100/100 mg were simulated using the WB-PBPK model.
PK variability of varying body size of the recommended dosage regimens of caspofungin in general patients, ICU and HI patients were assessed by creating virtual populations weighing 40-100 kg. Virtual ages of 18-95 years were groups, representatives of Asian and Westerner were simulated. Based on the WB-PBPK model, we could obtain the PK parameters including peak plasma concentrations (C max ), C min , AUC and CL of these patients under different weight conditions.
Dosage optimization
To describe caspofungin pharmacokinetic/pharmacodynamics (PK/PD) adequacy for the treatment of invasive Candida spp. and determine whether the different dosage regimens of caspofungin could achieve PK/PD targets in the general patient populations, ICU and HI patients. A MCS method was performed using the simulated data of WB-PBPK model. Through virtual simulation of Gastroplus, we obtained the AUC of different dosage regimens of these special patients. The MCS methods, the pharmacodynamic targets for Candida species (fAUC 0-24 /MIC ratio for C. albicans, C. glabrata and C. parapsilosis) and the minimum inhibitory concentration distributions for Candida species have been described previously [23] . The optimal dosage regimens were evaluated to compare the simulated probability of target attainment (PTA) and cumulative fraction of response (CFR) in these subjects. A CFR value -age regimen.
Results
Caspofungin PK
The WB-PBPK model for caspofungin was established according to the scheme of relevant tissue compartments of the disposition model. Simulations were conducted based on the physicochemical and in vitro data of caspofungin (Table 2) . Hepatic and renal caspofungin CL (Table 3) were calculated by the PKplus model, as described in the method section.
The observed (literate resources data) and mean simulated subjects are vividly presented in Figure 1 . The accuracy of the predictions are summarized in Table 3 . The predicted PK parameters were nearly consistent (<2-fold error) with the observed values (literate resources data). Accurately, using the in silico data, in vitro data, WB-PBPK model could simulate the plasma concentration-time profile following intravenous administration and predicted CL as inputs to the model, as shown in Figure 1 and Table 3 .
The established WB-PBPK model of caspofungin could predict the observed concentration-time profile (literate resources data) for all dose groups of different populations accurately (Figures 1-3, Supplementary Figure 1) . For all doses levels, the simulated peak concentrations seem to be underrated by 20% but they were within the error range. As shown in Supplementary Figure 1, (Figure 2 ). According to the GOF plot, we could see a good accuracy between predicted and observed data (literate resources data, Supplementary Figure 2A -B) . Only the simulated peak concentrations were undervalued in Gastroplus. For ICU patients with Child-Pugh B, ICU patients on CRRT and HI patients, when using the WB-PBPK distribution model to simulate plasma concentrations, a reasonable match to the measured concentration range was observed ( Figure  3 ). The GOF plot showed a good accuracy between predicted and observed data (literate resources data, Supplementary Figure 2C -D). The simulated peak levels seemed to be underestimated by 10%, which were within the error range. The simulated trough levels seemed to be underestimated by 10% in ICU patients with Child Pugh B and 5% in ICU patients on CRRT and mild HI patients compared with the observed data (literate resources and our research data), for moderate and observed data. The CL, V ss , t 1/2 , AUC, C max of different patients with different dosage regimens are shown in Table 3 . The fold-error of all dosage regimens were less than 2.
Virtual trial simulations PK parameters of general patients and ICU patients are shown in Table 3 . Particularly, the PK parameters of ICU patients were recorded. At steady state, the AUC of 70/35 mg, 70/70 mg, 100/100 mg of caspofungin in ICU patients were 74.5 mg·h/L, 155.5 mg·h/L, 218.4 mg·h/L, respectively. The AUC of moderate HI patients were 92.6 mg·h/L, 178.6 mg·h/L, 280 mg·h/L after simulation of the reduction dose of 50/25 mg and dose escalating of 70/70 mg, 100/100 mg. Supplementary Figure 3A , 3B and 3C showed the relationship between C max , C min , AUC, CL and BW with caspofungin 70/50 mg in general patients and ICU patients and 70/35 mg C min were constant in all investigated virtual patients and did not correlate to BW or other covariates. This was also valid for the CL. But C max and AUC began a slow decline with the increase of body weight. The variation tendency was not obvious in HI patients. As shown in Supplementary Figure 3D , patients with different ages showed no statistical difference in PK parameters. Compared with Westerner, C max in Asian showed a slight increase and C min showed a slight decrease in all of these general patients, ICU patients and HI patients (Supplementary  Figure 4) .
Optimization of the clinical dosage regimens
The WB-PBPK model coupled with a MCS showed the currently recommended dosage regimens of caspofungin in all C. albicans and C. glabrata, C. parapsilosis, a maintenance dose of 100/100 mg in ICU and mild HI patients and 70/70 mg in C. parapsilosis ( Figure 4 and Table 4 ).
Disscussion
Drug research based on the mathematical models becomes extremely important for the optimization of clinical dosage regimens in special populations, mostly by providing rea-sonable dose selection method and thereby offer a reliable models have been used for prediction of the pharmacokinetics in special populations for their strength in data integration and delivery of mechanistic insights and superior predictive power [24] . These models could explain phenomenons from the perspective of mathematical model principles and can be applied to forecast disease dependencies and can also be used to investigate the variability expected in different patient populations [24] . Based on the WB-PBPK models, this investiga--fungin. But most importantly, the study makes innovation in combining WB-PBPK model with MCS to optimize the clinical dosage regimens in special patients.
This article first describes the use of WB-PBPK modelling to assist research and clinical study of PK of caspofungin in ICU patients and HI patients. The approach which integrated drug-specific parameters such as logP, pK a , solubility and permeability and in vitro data such as plasma protein binding and blood-to-plasma concentration ratio was able to simulate the pharmacokinetics of caspofungin across multiple dose levels in different human populations with suitable accuracy. The methodology also provided a reliable way to understand the mechanisms underlying the pharmacokinetic processes of Based on the changes of caspofungin pharmacokinetic parameters and combined with MCS, an optimization of dosage regimens was developed in these special patients.
CRRT, the PK parameters from the WB-PBPK simulation were in good agreement with those of the observed (our research data). When combined with MCS method, the recommended dosage regimen (70/50 mg) is appropriate in these patients. But caspofungin maintenance dose should not be reduced to 35 mg in ICU patients with Child-Pugh B which based on the --age reduction to 35 mg daily following the 70 mg loading dose is reasonable for moderate HI patients with Child-Pugh score B. If the maintenance dose was reduced to 25 mg/d, C max will decrease (Mean: 5.5 mg/L, data were from the model simulation), which would affect the therapeutic effect of caspofungin. On the other hand, a maintenance dose increased to 50 mg/d will lead to a higher C min of 4.2 mg/L (data were from the model simulation), which would induce adverse reactions during the period of treatment.
With the increase of BW, PK of echinocandins might be altered due to changes in volume of distribution and/or CL. 
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Studies have shown that PK in obese patients might be altered due to a change of more fat tissue in relation to BW, change in liver metabolism and an increase in CL, and change in plasma protein constituents should also be considered [25] [26] [27] . Clinically, PK data of echinocandins in obese patients are scarce. One study demonstrated that patients weighing >80 kg are advised to receive caspofungin 70/70 mg [28] . In surgical ICU patients, weighing >75 kg were advised to receive a dosage regimen of 70/70 mg for lower C min (decreased by 28%) were predicted in these patients [7] . But in general ICU populations and hematopoietic stem cell transplantation patients (BW: range 50-99 kg) were discovered have no effect on caspofungin PK [9, 12] . With the WB-PBPK simulation, our study demonstrated that general and ICU patients weighing >70 kg are advised to receive 70/70 mg. But no dose adjustment is needed for mild and moderate HI patients weighing >70 kg for the recommended dosage regimens (70/50 mg for mild HI patients and 70/35 mg Candida spp., such as C. albicans and C. glabrata. For adult patients, age has no effect on the PK of all these patients, there Assignment of metabolism to transporters in the model is not considered in this paper but would be necessary for more detailed conclusions about the sources of variability in caspofungin PK. This would also require careful consideration of the demographics of the studied population and of other sources of variability. One study demonstrated that the intake approach of caspofungin into the liver is a biphasic process with a fast, reversible binding to the surface of hepatocytes and a slow transport through the active OATP1B1 [5] . Clinically, effective and reliable data on transporters and enzymes from in vitro experiments are needed in WB-PBPK models [29] , but we did not obtain utilizable K M and V max values of OATP1B1 for the transport of caspofungin in the literature. So data of V max and K M in vitro WB-PBPK model of caspofungin. Another limitation of this from the literate resources and we acquired them from the manuscripts, but not given by the original authors. In order to make up for the defects, we collected 508 trough concentrations from 161 patients (39 ICU patients with Child-Pugh B, 16 ICU patients on CRRT, 47 moderate HI patients and 68 mild HI patients) to evaluate the model and found that they all showed sufficient accuracy between predicted and observed data.
Conclusion
In conclusion, a WB-PBPK model for caspofungin was develmodel successfully predicted the intravenous and PK of caspofungin across multiple dose levels in normal human populations and special patients. This represents a case study that highlights the prospective applications of the WB-PBPK model combined with the MCS to provide clinical PK predictions and optimize the clinical dosage regimens. PK of caspofungin can be obtained before proceeding with clinical studies. Clinically, when BW is higher than 70 kg in ICU patients, an increasing maintenance dose of 70 mg every day should be considered in humans at lower exposures. Dose reduction of caspofungin in ICU Patients with Child Pugh B will result in suboptimal exposure. In the future, combined with other methods, the model could be used as a basis for further clinical investigations to enable a priori adjustment of drug dosing for maximal
